Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis.

I. Spriet,L. Delaere,K. Lagrou,W. Peetermans,J. Maertens,L. Willems
DOI: https://doi.org/10.1093/jac/dkp306
2009-10-01
Journal of Antimicrobial Chemotherapy
Abstract:and L180M are compensatory mutations that increase the fitness of hepatitis B viruses harbouring mutations in the YMDD domain of the viral polymerase. It is of interest that while the YMDD domain mutation M204V was present as a minority species at baseline, V173L and L180M co-existed with the wild type as a mixed sequence in these two positions. While it is known that entecavir does not select lamivudine-associated mutations de novo, it is clear from this patient that pre-existing mutations were selected rapidly and resulted in virological rebound. Failure of entecavir was said to be rare and to occur only after 1–2 years of therapy. Hence, this is a case of early virological hepatitis B rebound on entecavir, through selection of lamivudine-associated mutations, but without developing any further entecavir-associated mutations in a treatment-naive patient. We feel it is essential to perform baseline resistance profiling on all patients started on entecavir even if treatment naive. The sequence tracing also needs to be carefully scrutinized as the mutations may appear as a minority species not obviously visible on population sequencing analysis.
What problem does this paper attempt to address?